Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2023.106.26
- Author:
Yaoyao LIU
1
;
Jianlong MIAO
2
Author Information
1. Clinical Medical College of Jining Medical University, Jining 272000, China.
2. Pulmonary and Critical Care Medicine, Jining No. 1 People's Hospital, Jining 272000, China.
- Publication Type:Journal Article
- Keywords:
Epidermal growth factor receptor (EGFR) gene mutation;
Immunotherapy;
Lung neoplasms
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/genetics*;
Lung Neoplasms/genetics*;
ErbB Receptors/metabolism*;
Immunotherapy;
Mutation;
B7-H1 Antigen/genetics*;
Protein Kinase Inhibitors/pharmacology*;
Tumor Microenvironment
- From:
Chinese Journal of Lung Cancer
2024;26(12):934-942
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are currently the first-line standard of care for patients with non-small cell lung cancer (NSCLC) that harbor EGFR mutations. Nevertheless, resistance to EGFR-TKIs is inevitable. In recent years, although immune checkpoint inhibitors (ICIs) have significantly shifted the treatment paradigm in advanced NSCLC without driver mutation, clinical benefits of these agents are limited in patients with EGFR-mutated NSCLC. Compared with wild-type tumors, tumors with EGFR mutations show more heterogeneity in the expression level of programmed cell death ligand 1 (PD-L1), tumor mutational burden (TMB), and other tumor microenvironment (TME) characteristics. Whether ICIs are suitable for NSCLC patients with EGFR mutations is still worth exploring. In this review, we summarized the clinical data with regard to the efficacy of ICIs in patients with EGFR-mutated NSCLC and deciphered the unique TME in EGFR-mutated NSCLC.
.
